Dye test aims to improve ovarian cancer staging

NCT ID NCT04051502

Completed Knowledge-focused Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested if a special dye (ICG) can help surgeons find the first lymph nodes that ovarian cancer might spread to. 48 women having ovary surgery took part. The goal was to see if the dye works well for this purpose, which could help doctors better understand and stage the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADNEXAL MASS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADNEXAL MASS OVARIAN CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (Consent only)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Consent only )

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack (Consent only)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (Consent only)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Consent only)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (Consent only)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.